GW Pharma’s Latest Clinical Trial Successful, Stock Soars

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price.

According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” in patients with a particular type of epilepsy during phase III clinical trials.

On Monday, after news of the trials broke, the publicly traded company’s stock shot up 16% to a record high of 811 pence on the London Stock Exchange, Reuters reported. The news